MGX Stock Overview
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Metagenomi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.24 |
| 52 Week High | US$12.74 |
| 52 Week Low | US$1.61 |
| Beta | 0 |
| 1 Month Change | 78.02% |
| 3 Month Change | 18.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.57% |
Recent News & Updates
Shareholder Returns
| MGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 75.1% | -4.2% | -0.9% |
| 1Y | n/a | 3.0% | 27.6% |
Return vs Industry: Insufficient data to determine how MGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MGX performed against the US Market.
Price Volatility
| MGX volatility | |
|---|---|
| MGX Average Weekly Movement | 36.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGX's weekly volatility has increased from 22% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 207 | Brian Thomas | www.metagenomi.co |
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
Metagenomi, Inc. Fundamentals Summary
| MGX fundamental statistics | |
|---|---|
| Market cap | US$121.25m |
| Earnings (TTM) | -US$73.95m |
| Revenue (TTM) | US$55.08m |
2.2x
P/S Ratio-1.6x
P/E RatioIs MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGX income statement (TTM) | |
|---|---|
| Revenue | US$55.08m |
| Cost of Revenue | US$110.77m |
| Gross Profit | -US$55.69m |
| Other Expenses | US$18.26m |
| Earnings | -US$73.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | -101.11% |
| Net Profit Margin | -134.27% |
| Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparison